SignalSilence siRNA
SignalSilence® MARK2 siRNA I #6266
| Item # | Description | List Price | Web Price | QTY | Buy |
|---|
| Applications | Reactivity | Sensitivity | MW (kDa) | Source |
|---|---|---|---|---|
| H |
Applications Key:
Reactivity Key:
H = Human
Species cross-reactivity is determined by Western blot.
Description
SignalSilence® MARK2 siRNA I from Cell Signaling Technology (CST) allows the researcher to specifically inhibit MARK2 expression using RNA interference, a method whereby gene expression can be selectively silenced through the delivery of double stranded RNA molecules into the cell. All SignalSilence® siRNA products from CST are rigorously tested in-house and have been shown to reduce target protein expression by western analysis.
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Western Blotting
Western blot analysis of extracts from HeLa cells, transfected with 100 nM SignalSilence® Control siRNA (Unconjugated) #6568 (-) or SignalSilence® MARK2 siRNA I (+), using MARK2 Antibody #9118 (upper) or α-Tubulin (11H10) Rabbit mAb #2125 (lower). The MARK2 Antibody confirms silencing of MARK2 expression, while the α-Tubulin (11H10) Rabbit mAb is used as a loading control.
Directions for Use
CST recommends transfection with 100 nM MARK2 siRNA I 48 to 72 hours prior to cell lysis. For transfection procedure, follow protocol provided by the transfection reagent manufacturer. Please feel free to contact CST with any questions on use.
Background
Microtubule associated proteins regulate the stability of microtubules and control processes such as cell polarity/differentiation, neurite outgrowth, cell division and organelle trafficking (1). The MARK (MAP/microtubule affinity-regulating kinases) family (MARK1-4) of serine/threonine kinases was identified based on their ability to phosphorylate microtubule-associated proteins (MAPs) including tau, MAP2 and MAP4 (2-6). MARK proteins phosphorylate MAPs within their microtubule binding domains, causing dissociation of MAPs from microtubules and increased microtubule dynamics (2-4). In the case of tau, phosphorylation has been hypothesized to contribute to the formation of neurofibrillary tangles observed in Alzheimer's disease. Overexpression of MARK leads to hyperphosphorylation of MAPs, morphological changes and cell death (4). The tumor suppressor kinase LKB1 phosphorylates MARK and the closely related AMP-kinases within their T-loops, leading to increased activity (7).
- Drubin, D.G. and Nelson, W.J. et al. (1996) Cell84, 335 - 44.
- Illenberger, S. et al. (1996) J Biol Chem271, 10834 - 43.
- Drewes, G. et al. (1995) J Biol Chem270, 7679 - 88.
- Drewes, G. et al. (1997) Cell89, 297 - 308.
- Kato, T. et al. (2001) Neoplasia3, 4 - 9.
- Trinczek, B. et al. (2004) J Biol Chem279, 5915 - 23.
- Lizcano, J.M. et al. (2004) EMBO J23, 833 - 43.
Application References
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
Companion Products
- 6201 SignalSilence® Control siRNA (Fluorescein Conjugate)
- 6568 SignalSilence® Control siRNA (Unconjugated)
- 9118 MARK2 Antibody
This product is for in vitro research use only and is not intended for use in humans or animals. This product is not intended for use as therapeutic or in diagnostic procedures.
